Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6766 to 6780 of 7691 results

  1. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued [GID-TA10018]

  2. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued [GID-TA10105]

  3. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued [GID-TAG440]

  4. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

  5. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued [GID-TA10180]

  6. Venous leg ulcers - new treatments [ID394]

    Discontinued [GID-TAG370]

  7. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued [GID-TA10242]

  8. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

  9. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued [GID-TAG479]

  10. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued [GID-TA10109]

  11. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued [GID-TAG379]

  12. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued [GID-TA10267]

  13. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued [GID-TA10499]

  14. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued [GID-TA10028]